Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 31 Colorectal Neoplasms 18 Carcinoma, Hepatocellular 18 Stomach Neoplasms 12 Esophageal Squamous Cell Carcinoma 12 Squamous Cell Carcinoma of Head and Neck 9 Neoplasm Metastasis 9 Advanced Solid Tumor 9 Lung Neoplasms 7 Head and Neck Neoplasms 7 Rectal Neoplasms 5 Esophageal Neoplasms 5 Small Cell Lung Carcinoma 4 Neoplasms 4 Nasopharyngeal Carcinoma 4 Melanoma 4 Solid Tumor 3 Lymphoma, Follicular 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Biliary Tract Neoplasms 3 Adenocarcinoma 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Extranodal NK-T-Cell 2 Lymphoma 2 Hodgkin Disease 2

Interventions

Mitomycin 2 tislelizumab 1 molgramostim 1 cryoprecipitate coagulum 1 Tacrolimus 1 Standard of Care 1 Specimen Handling 1 Sirolimus 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 Hyperthermic Intraperitoneal Chemotherapy 1 Fluorouracil 1 CTLA-4 Antigen 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pseudomyxoma Peritonei × tislelizumab × 1 year × Clear all

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡